|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Section of Hematology/Oncology, University of
Chicago, Chicago, IL.
The (11;19)(q23;p13.1) translocation in acute leukemia leads to the
generation of a chimeric protein that fuses MLL to the transcriptional
elongation factor ELL. A novel protein was isolated from a yeast
2-hybrid screen with ELL that was named EAF1 for ELL-associated factor
1. Using specific antibodies, the endogenous EAF1 and ELL proteins were
coimmunoprecipitated from multiple cell lines. In addition, endogenous
EAF1 also exhibited the capacity to interact with ELL2. Database
comparisons with EAF1 identified a region with a high content of
serine, aspartic acid, and glutamic acid residues that exhibited
homology with the transcriptional activation domains of several
translocation partner proteins of MLL, including AF4, LAF4, and AF5q31.
A similar transcriptional activation domain has been identified in this
region of EAF1. By confocal microscopy, endogenous EAF1 and ELL
colocalized in a distinct nuclear speckled pattern. Transfection of the
MLL-ELL fusion gene delocalized EAF1 from its nuclear
speckled distribution to a diffuse nucleoplasmic pattern. In leukemic
cell lines derived from mice transplanted with
MLL-ELL-transduced bone marrow, EAF1 speckles were not
detected. Taken together, these data suggest that expression of the
MLL-ELL fusion protein may have a dominant effect on the normal
protein-protein interactions of ELL.
(Blood. 2001;98:201-209) The ELL gene was first identified as a
fusion partner gene of MLL in the (11;19)(q23;p13.1)
translocation, a recurring chromosomal aberration in acute myeloid
leukemia.1 Subsequent studies revealed that ELL functions
as an RNA polymerase II (Pol II) transcriptional elongation
factor.2 As a result of the (11;19)(q23;p13.1)
translocation, an MLL-ELL chimeric protein is formed that contains the
amino-terminal region of MLL, including its AT hooks, methyltransferase
domain, and repression domain, fused to amino acids 46 to 621 of ELL, including its elongation domain and a lysine-rich region within ELL.
ELL2 was identified by sequence homology to ELL and exhibits similar
activities to ELL in transcriptional elongation assays.3 However, ELL2 has not been observed in association with chromosome translocations in leukemia or in other malignancies. In addition to ELL
and ELL2, several different factors with elongation activity have been
identified including TFIIS, P-TEFb, TFIIF, Elongin, and FACT. TFIIS and
P-TEFb each prevent specific types of transcriptional arrest. TFIIS is
involved in the maintenance of transcriptional fidelity and P-TEFb
protects against the inhibition of elongation by DSIF.4,5
FACT facilitates elongation through its interactions with
chromatin.6 In contrast, ELL, ELL2, TFIIF, and
Elongin function as general elongation factors and serve to
prevent transient pausing by Pol II.7
More than 30 different recurring cytogenetic aberrations that affect
the MLL gene at 11q23 have been described.8,9
The critical feature of these chromosomal rearrangements is the
generation of a chimeric transcript consisting of 5' MLL and
3' sequences of the gene on the partner chromosome. The functions of
most MLL partner genes are not yet known. Although no
consistent homologies or motifs among the partner gene sequences have
been identified that might explain how their fusion to MLL
results in leukemia, certain groups of partner genes have similar
features. These include ENL and AF9, which are
serine and proline rich and share extensive amino acid
homology.10,11 AF4, LAF4, and AF5q31
are also rich in serines and prolines and exhibit homology with
ENL and AF9.12,13 AF4,
LAF4, ENL, and AF9 contain transcriptional
activation domains with similar properties in reporter gene
assays.14,15 Other families of MLL
partner genes include CBP and P300, which
function as transcriptional coactivators and have intrinsic histone
acetyltransferase activity.16,17 Expression of the
MLL-AF9, MLL-ENL, MLL-CBP, and
MLL-ELL fusion genes in mouse models results in the
development of acute myeloid leukemia.18-21
The pathways perturbed by the expression of MLL fusion genes
remain unclear. In view of the large number and diverse nature of
MLL partner genes, one hypothesis is that MLL
fusion genes disrupt normal functions of MLL. Alternatively,
these MLL fusions may dominantly affect functions of the
partner genes. In this study, we characterize a novel protein
named EAF1 for ELL-associated factor 1 that coimmunoprecipitated as a
complex with ELL and colocalized with ELL in a distinct nuclear
speckled pattern in multiple cell types. The EAF1 speckles
were delocalized by transient expression of MLL-ELL and were
not detectable in cell lines derived from MLL-ELL leukemic
mice. These data suggest that MLL fusion genes have the
capacity to exhibit dominant effects on the normal protein-protein interactions of MLL partner genes.
Yeast 2-hybrid interaction assay
Nucleotide sequencing
Northern blot analysis Multiple tissue Northern blots (Clontech) containing approximately 2 µg per lane of purified poly(A)+ RNA from different human tissues were hybridized for 1 hour with an [ -32P] dCTP-labeled EAF1 cDNA probe prepared using
random primers (Stratagene, La Jolla, CA). Filters were washed
with 2 × saline sodium citrate (SSC) and 0.1% sodium dodecyl sulfate
(SDS) for 40 minutes with agitation at room temperature, and with
0.1 × SSC and 0.1% SDS for 40 minutes at 50°C, and then
autoradiographed. To normalize for the relative amount of RNA in each
lane, the blots were stripped and then reprobed with a human  -actin
cDNA probe.
Production of a monoclonal antibody to EAF1 To produce a histidine-tagged EAF1 protein in bacteria, the full-length open reading frame of EAF1 was cloned into the pET-19b expression vector (Novagen, San Diego, CA) and transformed in the Escherichia coli strain BL21(DE3). The histidine-tagged EAF1 fusion protein was purified on a nickel column and eluted in 1 M imidazole, 500 mM NaCl, 20 mM Tris-HCl, pH 7.9. A monoclonal antibody to EAF1 was generated using standard methods.Affinity purification of rabbit polyclonal ELL antisera Approximately 1 mg GST-ELL protein was electrophoresed on a preparative gel, transferred to nitrocellulose, blocked in tris buffered saline with 0.05% Tween 20 (TBST) containing 10% normal goat serum, and incubated with 2 mL ELL antiserum overnight at 4°C. The strips were then washed in 1% Tween and then phosphate-buffered saline (PBS). Bound antibody was eluted in 0.2 M glycine, pH 2.8, neutralized with 1 M Tris, pH 10.5, and dialyzed against PBS.Cell culture, transient transfection, and immunoprecipitation Human 293 and HeLa cells were transiently transfected by the calcium phosphate method using 20 µg plasmid DNA. Cell pellets were resuspended in 1 mL TEN (40 mM Tris, 1 mM EDTA, 150 mM NaCl) buffer, centrifuged for 5 minutes at 1200g at 4°C, lysed with 500 µL NETN (100 mM NaCl, 20 mM Tris, pH 8.0, 1 mM EDTA, and 0.2% NP-40) containing a cocktail of protease inhibitors (Sigma Chemical, St Louis, MO), incubated on ice for 10 minutes, and centrifuged at 2500g for 30 minutes at 4°C. To precipitate the complexes, supernatants were precleared with 30 µL protein A/G agarose beads (Santa Cruz, Santa Cruz, CA) for 30 minutes and then incubated for 1 hour with the indicated antibody. We then added 30 µL of a 50% slurry of protein A/G agarose beads, incubated overnight at 4°C, washed 5 times at 4°C with lysis buffer, boiled in Laemmli sample buffer, fractionated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to nitrocellulose membranes (Biorad). Blots were blocked in Tris-buffered saline (TBS) with 0.05% Tween 20 and 5% nonfat milk followed by incubations with the indicated primary and secondary antibodies in this buffer. To obtain normal murine hematopoietic progenitor cells, bone marrow cells were harvested from C57Bl/6 mice, incubated with magnetically labeled antibodies to CD5, B220, Cd11b, Gr-1, and TER119, followed by depletion of labeled differentiated cells by passage through a magnetic column (Stem Cell Technologies, Vancouver, BC, Canada).Immunofluorescence HeLa cells were grown for 24 hours on glass coverslips coated with 0.2% gelatin, washed with PBS, and then fixed in one of 4 conditions: 3.7% formaldehyde in PBS at room temperature, 1.75% paraformaldehyde in PBS at room temperature, 20°C acetone, or a 1:1
mixture of methanol and acetone at room temperature. Incubation with
the primary and secondary antibodies, quenching, and staining with
4'6-diamidino-2-phenylindole (DAPI) was performed as previously described.24 Fluorescence images were obtained with a
Zeiss Axiophot microscope and confocal images were obtained with a
Zeiss/NORAN system.
Antibodies We used each of the 4 different fixation methods outlined above with the affinity purified polyclonal anti-ELL antisera at a 1:500 dilution and the anti-EAF1 monoclonal antibody at a 1:100 dilution. For dual labeling of HeLa cells, the following antibody dilutions and fixative conditions were used: MLL (kindly provided by Dr D. Mason) at 1:4 with paraformaldehyde, PML (Santa Cruz) at 1:100 with paraformaldehyde, CBP (Santa Cruz) at 1:200 with formaldehyde, AF4 (kindly provided by Dr J. Kersey) at 1:50 with formaldehyde, nucleoli (Chemicon, Temecula, CA) at 1:1000 with paraformaldehyde, SC35 (Pharmingen, San Diego, CA) at 1:2000 with20°C acetone,
8WG16 (BAbCO, Richmond, CA) against the large subunit of Pol II
at 1:2000 with paraformaldehyde, and H5 (BAbCO) against the
hyperphosphorylated CTD of Pol II at 1:1000 with 20°C acetone. For
the immunoprecipitations, the cell extracts were incubated with the
EAF1 monoclonal or the isotype control monoclonal at 1:10, and with the
anti-FLAG monoclonal (Sigma) at 1:500. For the Western blots, the
membranes were incubated with the preimmune and polyclonal anti-ELL
antisera at 1:000, anti-FLAG-M2 at 1:1000, anti-EAF1 at 1:10, isotype
control at 1:10, anti-GAL4 at 1:500.
Chloramphenicol acetyltransferase assays The 293 cells were transfected with Lipofectamine (Gibco BRL, Grand Island, NY) using 1.5 µg of a GAL4-E1bCAT or E1bCAT reporter plasmid, 0.5 µg of a-gal plasmid, and 2 µg of a plasmid
containing the GAL4 DNA binding domain fused to EAF1, truncations of
EAF1, or the activation domains of AF4 and LAF-4. The GAL4 DNA binding domain consists of GAL4 amino acids 1 to 147, the GAL4-E1bCAT reporter
plasmid contains 5 GAL4 binding sites 5' to an E1bTATA element, and the
E1bCAT reporter plasmid contains the E1bTATA element
alone.25 Total cell lysates were prepared from cells harvested 48 hours after transfection, and expression of each construct
was confirmed by Western blot. The -galactosidase values were used
to normalize the amount of cell lysate for enzyme-linked immunosorbent
assay (ELISA) analysis. CAT activity was assayed using an ELISA kit
following the manufacturer's recommendations (Boerhringer Mannheim,
Sunnyvale, CA). CAT activity was measured using a Molecular
Dynamics ELISA reader. Transfections and CAT assays were repeated at
least 3 times with each set of constructs. Fold activation was
expressed as the ratio of the absolute values obtained from
samples cotransfected with a reporter plasmid containing GAL4-E1bCAT
versus those cotransfected with a reporter plasmid containing E1bCAT
(lacking GAL4-DNA binding sites).
Isolation of EAF1 We used a yeast 2-hybrid screen to identify proteins that interact with ELL. We isolated 6 identical clones that contained the open reading frame of a novel gene that we named EAF1 for ELL-associated factor 1. To verify the interaction of EAF1with ELL and to exclude the possibility that EAF1 might either interact with other proteins in a nonspecific manner or activate the HIS3 or-gal reporters by itself, we retransformed pGAD10-EAF1
with pAS2-1-ELL and a series of 4 unrelated proteins cloned in the pAS2-1 vector. These assays confirmed the specificity of the
interaction of EAF1 with ELL in the yeast 2-hybrid system.
Searches of GenBank with the EAF1 sequence revealed that this gene had
not been previously identified. The clones that were isolated from the
screen contained 989 nucleotides with a predicted open reading frame of
804 nucleotides with a 5' untranslated region of 157 nucleotides and a
3' untranslated region of 28 nucleotides. We compared EAF1 sequence to
the EST database and identified several matching clones. Using 3 EST
clones, we were able to obtain approximately 1784 nucleotides of
additional untranslated sequence 5' to the predicted open reading
frame. The predicted protein of EAF1 contains 268 amino acids and has
an estimated pI of 5.06 (Figure 1A).
Database searches using the BLASTP and DeCypher II Smith Waterman
algorithms revealed a region of limited homology to the LAF4, AF4, and
AF5q31 proteins. This homology is highest from amino acids 188 through 216 of EAF1, a region rich in serine, aspartic acid, and glutamic acid
residues (Figure 1B).
Northern blot analysis To determine the pattern of expression of EAF1 messenger RNA (mRNA) in different tissues, a human multiple tissue Northern blot was hybridized with the 989-bp EAF1 cDNA fragment isolated from the bone marrow library. A single 4.5-kb transcript could be visualized in all tissues examined except for the thymus, which demonstrated only minimal expression (Figure 1C). An additional smaller transcript of approximately 2.0 kb could be detected in testis and skeletal muscle. The size of the predominant message detected on the Northern blots exceeds the size of the EAF1 contig that we assembled from the bone marrow library screen and the EST clones, indicating that an additional 5' or 3' untranslated sequence has not yet been isolated.EAF1 interacts with ELL and ELL2 in vivo To examine the potential of the endogenous EAF1 protein to interact with ELL and ELL2, we transfected 293 cells with FLAG-tagged ELL and ELL2 constructs. As a control, we also transfected 293 cells with FLAG-tagged versions of ENL and AF4. The cell lysates were immunoprecipitated with either the EAF1 antibody or an isotype control antibody and then immunoblotted with the FLAG antibody. We observed that the EAF1 antibody could coprecipitate ELL and ELL2, but not the ENL and AF4 controls (Figure 2A). In a reciprocal experiment, we immunoprecipitated the cell lysates with the FLAG antibody and immunoblotted with either the EAF1 antibody or an isotype control. The transfected ELL and ELL2 proteins coimmunoprecipitated with endogenous EAF1, which migrated at approximately 43 kd (Figure 2B). However, no band was detectable in the ENL and AF4 controls. In the t(11;19), amino acids 46 to 621 of ELL fuse to the N-terminus of MLL. To determine whether the capacity to bind EAF1 was retained by these ELL sequences, we transfected a FLAG-tagged construct containing amino acids 46 to 621 of ELL. Similar to full-length ELL, amino acids 46 to 621 retained the capacity to precipitate endogenous EAF1 (Figure 2C). To determine the region of ELL that interacts with EAF1, we transfected a series of FLAG-tagged constructs that contained different regions of ELL. The 293 cells were immunoprecipitated with the FLAG antibody and probed with the EAF1 monoclonal antibody. Endogenous EAF1 coprecipitated with the region of ELL (amino acids 46-621) that fuses to MLL in (11;19)(q23;p13.1) translocations. The interaction domain localized to amino acids 401 to 621 of ELL (Figure 2C).
Coimmunoprecipitation of endogenous ELL and EAF1 To exclude an artifact related to transfection and to establish whether endogenous ELL and EAF1 interact in vivo, we examined untransfected 293 and HeLa cells. Cell lysates were immunoprecipitated with the EAF1 antibody or with an isotype control. These immunoprecipitates were then immunoblotted with the ELL antiserum or with its preimmune serum. We detected a single band corresponding to endogenous ELL in the cell lysates immunoprecipitated with the EAF1 monoclonal antibodies and probed with the ELL antiserum, whereas the control lanes were negative (Figure 3A). Thus, ELL and EAF1 have a direct physical interaction in vivo.
ELL forms a stable complex with EAF1 To determine the stability of the ELL/EAF1 complex, we examined the stringency of this interaction under conditions of high salt, increased levels of nonionic detergent, or the addition of ionic detergent. We varied the concentration of NaCl or NP-40 in the NETN buffer or added SDS to NETN for the washes of the immunoprecipitated complexes. The ELL/EAF1 complex remained intact when the cell lysates were washed with NETN buffer containing up to 2% of the nonionic detergent NP-40 or in conditions of high salt up to 1.2 M NaCl (Figure 3B). The ELL/EAF1 complex was also stable when washed with NETN with the addition of the ionic detergent SDS at 0.1%. At concentrations of 0.5% SDS added to the NETN, the complex was only partially dissociated, and disruption of the ELL/EAF1 complex required the addition of 1% SDS to the NETN buffer.EAF1 contains a transactivation domain in its region of homology to AF4 and LAF4 To investigate the potential of EAF1 to function as a transcriptional activator, we generated fusions to the GAL4 DNA binding domain with full-length EAF1, EAF1 deletion mutants, and the previously described activation domains of AF4 and LAF4 (Figure 4A). These constructs were then cotransfected into 293 cells with either a GAL4-E1bCAT or a control E1bCAT reporter construct and a-galactosidase plasmid. Cell lysates
were analyzed in a CAT ELISA assay, normalizing the amount of lysate
for each assay by measuring -galactosidase expression. Expression of
each effector construct was confirmed by Western blot analysis (Figure
4B). We observed that full-length EAF1 could function as a
transactivator. Using the EAF1 deletion mutants, we mapped this
activity to a region spanning 86 amino acids that includes the region
rich in serine, glutamic acid, and aspartic acid residues that is
homologous to AF4 and LAF4 (Figure 4C). This region showed the
strongest activity, exhibiting a 29.4 ± 8.9-fold increase in
activation compared to the control. The homologous regions of AF4 and
LAF4 exhibited comparable activity, namely 34 ± 12.7- and
25.5 ± 1.01- fold activation, respectively.
Colocalization of ELL and EAF1 To determine the subcellular localization of EAF1, we incubated the adherent cell lines HeLa and 293 with the EAF1 antibody and observed that EAF1 exhibited a speckled nuclear pattern in nondividing cells and a diffuse pattern in dividing cells (Figure 5E,F). Costaining with DAPI revealed that EAF1 localized exclusively to the nucleus. Using a polyclonal antiserum to ELL, we had previously observed that ELL also localized to the nucleus. To assess the subnuclear localization of ELL more precisely, we used the affinity-purified ELL antiserum and observed a speckled pattern in the nucleus similar to that of EAF1 (Figure 5B,C). To determine whether ELL and EAF1 might colocalize, we undertook confocal microscopy. To exclude artifact, we used the fluorochromes Cy2 and Cy5, which have no overlap in spectral emission. We observed that the nuclear speckles of ELL and EAF1 colocalized; the pattern of the speckles was indistinguishable for both ELL and EAF1 (Figure 5I). Moreover, we could detect colocalization of ELL and EAF1 speckles using several different fixation techniques, including formaldehyde, paraformaldehyde, methanol, and acetone.
To investigate whether other proteins might also be components of the
ELL/EAF1 speckles, we incubated HeLa cells with antibodies to several
potential candidate proteins and assessed for colocalization by
confocal microscopy (Figure 6). We
examined antibodies to MLL, PML, CBP, SC-35, nucleoli, and to the
hypophosphorylated and hyperphosphorylated forms of Pol
II. However, we did not detect colocalization of ELL/EAF1 with any of
these proteins.
Expression of the MLL-ELL fusion protein delocalizes EAF1 from nuclear speckles To determine the effects of expression of the MLL-ELL fusion protein on the subcellular localization of endogenous EAF1, we transiently transfected HeLa cells with FLAG-tagged constructs containing full-length ELL, the amino-terminus of MLL, or the MLL-ELL fusion protein. We observed an increase in the number of both ELL and EAF1 speckles in cells transiently transfected with FLAG-ELL (Figure 7). In the transiently transfected cells that overexpress ELL, numerous speckles appear to coalesce, resulting in a brighter, more diffuse nuclear pattern compared to that seen with endogenous ELL. We observed a similar nuclear staining pattern in cells transiently transfected with FLAG-ELL2 (data not shown). In cells transfected with the amino-terminus of MLL, we observed no change in the pattern of EAF1 speckles. In contrast, in cells transfected with the MLL-ELL fusion protein, we observed a fainter, more diffuse nucleoplasmic distribution of EAF1, with an absence of bright speckles (Figure 7). Recently, we have undertaken retroviral bone marrow infection of MLL-ELL to immortalize hematopoietic progenitor cells in vitro and to generate a mouse model of MLL-ELL leukemia. To determine the subcellular distribution of EAF1 in cells that stably express MLL-ELL, we examined cell lines derived from leukemic mice and from immortalized hematopoietic progenitor cells. As in the transiently transfected cells, we observed only a diffuse nucleoplasmic pattern of expression for EAF1, but no detectable speckles (Figure 8C,D). However, a punctate pattern of expression could be detected with antibodies to both MLL and ELL in these cells. A subset of the speckles colocalized, suggesting that these antibodies were detecting the MLL-ELL fusion protein in addition to the wild-type MLL and ELL proteins (Figure 8E,F). To confirm the normal distribution of EAF1 and ELL in murine hematopoietic cells, we incubated normal murine bone marrow progenitor cells as well as the murine hematopoietic progenitor cell line BaF/3 with antibodies to ELL and EAF1 and observed that ELL and EAF1 colocalized in nuclear speckles (Figure 8A,B).
We have isolated and characterized EAF1, a novel protein that interacts with ELL. Northern blot analysis revealed that the EAF1 gene transcript is expressed broadly with the exception of the thymus. Using a monoclonal antibody generated to EAF1 and an affinity-purified polyclonal antiserum to ELL, we have coimmunoprecipitated the endogenous ELL and EAF1 proteins, demonstrating that these proteins have a direct physical interaction in vivo. The ELL/EAF1 complex remained stable in conditions of high salt and in high levels of nonionic detergents. In transient transfections of epitope-tagged ELL2, we also found that endogenous EAF1 has the potential to bind to ELL2, suggesting that EAF1 binding may be important to the functions of both ELL and ELL2. Using the BLASTP and the DeCypher II algorithms to compare the predicted amino acid sequence of EAF1 to that of known proteins, we identified several translocation partner proteins of MLL including LAF4, AF4, and AF5q31. The homology within these proteins is limited to a region of EAF1 that is rich in serine, aspartic acid, and glutamic acid residues. In the database searches, the LAF4 protein exhibited the greatest homology to this domain of EAF1. LAF4 was identified as a lymphoid-specific homologue of AF4, and was recently found to be involved in the t(2;11) chromosome translocation.26,27 FMR2, another member of the AF4 family, is associated with the X-linked mental retardation fragile site syndrome (FRAXE), but is not known to be involved in chromosome translocations.28 In contrast to EAF1, members of the AF4 family share extensive homology with each other outside of their respective transactivation domains. In addition to the homologous amino acid sequence, EAF1, LAF4, AF5q31, and AF4 exhibit a similar overall amino acid composition within the region of homology. Moreover, a transcriptional activation domain has been mapped to this region in each of these proteins. In view of the homology of EAF1 to the transcriptional activation domains of several MLL partner proteins, we examined EAF1 for the potential to function as a transactivator. We found that the full-length EAF1 protein could function as a relatively weak activator of transcription. This activity mapped to the C-terminal one third of EAF1, which contains the region of homology to AF4 family members. Compared to the full-length EAF1 protein, the potency of transcriptional activation was much greater in the C-terminal third of EAF1. A direct comparison of the homologous regions of EAF1, LAF4, and AF4 revealed that the transcriptional activation potential of these proteins was quite similar. Recently, ELL was found to interact with p53 in a yeast 2-hybrid screen.29,30 Confirmation of this interaction was obtained by pull-down assays using transiently transfected epitope-tagged versions of ELL and p53. In addition, 3 proteins with approximate molecular weights of 20, 30, and 45 kd were found to coprecipitate with ELL from rat liver nuclear extracts.31 The 30-kd protein, named EAP30, was purified and peptide microsequences obtained. EAP30 exhibits amino acid homology with the yeast SNF8 protein. Comparison of the amino acid sequence reveals no homology between EAF1 and EAP30. It is unclear whether EAF1 represents the 45-kd protein identified as part of the complex with ELL in the rat liver nuclear extract. However, this protein appears to migrate slightly above a 45-kd marker, whereas EAF1 migrates at approximately 43 kd on SDS-PAGE. By confocal microscopy, ELL and EAF1 speckles colocalized within the nucleus, indicating that ELL and EAF1 exist in a distinct nuclear complex. However, we cannot exclude that small amounts of these 2 proteins may exist outside of the nuclear speckles. At this time, it is not clear whether the ELL/EAF1 nuclear speckles represent storage forms of these proteins or a distinct substructure within the nucleus. In dividing cells, ELL and EAF1 were distributed diffusely, consistent with the dissolution of the nuclear membrane during cell division. The disappearance of the speckles in dividing cells may be associated with the lack of transcription by Pol II during mitosis. The ELL/EAF1speckles were distinct from the other nuclear proteins that we have examined. We found no colocalization with the MLL protein, which exhibits a punctate nuclear distribution, suggesting that ELL and MLL are in distinct compartments within the nucleus.32 We examined several other proteins involved in chromosome translocations that did not colocalize with ELL and EAF1, including PML, AF4, and CBP. The AF4 protein exhibits a punctate nuclear pattern by immunofluorescence and is a partner protein of MLL in (4;11) translocations.33 CBP is a transcriptional coactivator and a partner protein of MLL in (11;16) translocations. Recently, several lines of evidence have linked RNA processing and splicing to transcription by Pol II. In addition, splicing factors have been shown to localize in speckled domains within the nucleus.34 However, we found that ELL/EAF1 speckles did not colocalize with the SC-35 splicing factor. We also found that neither phosphorylated form of Pol II colocalized with ELL/EAF1. Hyperphosphorylation of Pol II is associated with transcriptional elongation. The hypophosphorylated form of Pol II localizes relatively diffusely within the nucleus, whereas the hyperphosphorylated form exhibits a speckled nuclear distribution.35 Because other proteins involved in transcription have been identified in a speckled distribution in the nucleus, the ELL/EAF1 speckles may have functional importance. The nuclear speckles that contain splicing factors such as SF2/ASF or SC-35 appear to supply these factors to genes actively transcribed by Pol II.34 Similarly, a potential role for the ELL/EAF1 speckles may be to supply elongation factors to the transcription complex. We observed an increase in the number of EAF1 speckles in cells
transfected with full-length ELL, suggesting that
overexpression of ELL may affect the expression of
endogenous EAF1. Strikingly, EAF1 speckles were not observed
in HeLa cells transiently transfected with the MLL-ELL
fusion gene. In contrast, transfection of the amino-terminus of
MLL did not affect the distribution of EAF1 nuclear
speckles. At this time, human cell lines derived from MLL-ELL leukemia cells have not been generated. Thus, we
examined cell lines derived from leukemic mice transplanted with bone
marrow infected with an MLL-ELL retrovirus or from primary
hematopoietic progenitor cells that were immortalized in vitro with the
MLL-ELL retrovirus. In both of these cell lines, expression
of MLL and ELL could be detected with specific antibodies. We observed
partial colocalization of MLL and ELL, suggesting that these antibodies were both recognizing the MLL-ELL fusion protein. In addition, we could
detect nonoverlapping nuclear staining for both MLL and ELL, indicating
the presence of wild-type MLL and ELL expression in these cells.
However, we observed a diffuse nucleoplasmic staining pattern for EAF1,
with no detectable speckles. A similar phenomenon is observed in acute
promyelocytic leukemia as a result of the (15;17) translocation. In
acute promyelocytic leukemia cell lines, nuclear body structures are
disrupted with delocalization of PML and other nuclear body
proteins.36,37 This occurs despite the expression of
wild-type PML in addition to PML-RAR Using a hematopoietic progenitor immortalization assay, we have recently undertaken a structure-function analysis of the ELL gene.38 We sequentially fused individual regions of ELL to 5' MLL and examined their capacity to immortalize progenitor cells in vitro. Whereas the amino-terminal elongation domain within ELL was dispensable for immortalization, the carboxy-terminus of ELL was necessary and sufficient to immortalize hematopoietic progenitor cells. The carboxy-terminus of ELL contains its EAF1 interaction domain, suggesting that retention of this protein-protein interaction domain may be relevant to leukemic transformation by MLL-ELL. However, this region of ELL may also mediate interactions with other proteins or contain additional functional motifs. The functional significance of the interaction of ELL with EAF1 remains to be defined. ELL has been shown to function as a Pol II elongation factor in vitro, and we now show that EAF1 has the capacity to function as a transcriptional activator. Previously, the functions of transcriptional activation and elongation factors have been found to overlap. In assays of processivity through transcriptional termination sites within c-myc and human immunodeficiency virus 2, transactivators including VP-16 and E1a have been shown to stimulate elongation by Pol II.39 In addition, the transcriptional activation domains of VP16 and heat shock factor 1 have been found to function not only in initiation but also in elongation by Pol II on an hsp70 gene template.40 However, mutational analysis within these activation domains revealed that distinct residues were essential for either initiation or elongation. Similarly, the ELL/EAF1 complex may function in both transcriptional activation and elongation. Future studies of ELL, EAF1, and other MLL partner proteins will be necessary to define the specific pathways that are regulated by these factors.
We are grateful to Dr D. Mason, Dr J. Kersey, and Dr P. Domer for generously providing reagents. We would like to thank Carol McShan and the University of Chicago Frank Fitch Monoclonal Antibody Facility (supported by grant CA14599 from the National Cancer Institute) and the Al Robin Laser Scanning Confocal Microscopy Core of the University of Chicago Digestive Disease Center.
Submitted November 30, 2000; accepted March 2, 2001.
Supported by grants from the National Institutes of Health (CA78431), Burroughs Wellcome Fund, Cancer Research Foundation, American Cancer Society Illinois Division, and the family of Robert A. Chapski.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Michael J. Thirman, Section of Hematology/Oncology, University of Chicago, 5841 S Maryland Ave, MC2115, Chicago, IL 60637; e-mail: mthirman{at}medicine.bsd.uchicago.edu.
1.
Thirman MJ, Levitan DA, Kobayashi H, Simon MC, Rowley JD.
Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia.
Proc Natl Acad Sci U S A.
1994;91:12110-12114 2. Shilatifard A, Lane WS, Jackson KW, Conaway RC, Conaway JW. An RNA polymerase II elongation factor encoded by the human ELL gene. Science. 1996;271:1873-1876[Abstract].
3.
Shilatifard A, Duan DR, Haque D, Florence C, Schubach WH, Conaway JW.
ELL2, a new member of an ELL family of RNA polymerase II elongation factors.
Proc Natl Acad Sci U S A.
1997;94:3639-3643
4.
Jeon C, Agarwal K.
Fidelity of RNA polymerase II transcription controlled by elongation factor TFIIS.
Proc Natl Acad Sci U S A.
1996;93:13677-13682 5. Wada T, Takagi T, Yamaguchi Y, Watanabe D, Handa H. Evidence that P-TEFb alleviates the negative effect of DSIF on RNA polymerase II-dependent transcription in vitro. EMBO J. 1998;17:7395-7403[CrossRef][Medline] [Order article via Infotrieve]. 6. Orphanides G, Wu WH, Lane WS, Hampsey M, Reinberg D. The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins. Nature. 1999;400:284-288[CrossRef][Medline] [Order article via Infotrieve]. 7. Reines D, Conaway JW, Conaway RC. Mechanism and regulation of transcriptional elongation by RNA polymerase II. Curr Opin Cell Biol. 1999;11:342-346[CrossRef][Medline] [Order article via Infotrieve].
8.
Thirman MJ, Gill HJ, Burnett RC, et al.
Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations.
N Engl J Med.
1993;329:909-914 9. DiMartino JF, Cleary ML. MLL rearrangements in haematological malignancies: lessons from clinical and biological studies. Br J Haematol. 1999;106:614-626[CrossRef][Medline] [Order article via Infotrieve]. 10. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell. 1992;71:691-700[CrossRef][Medline] [Order article via Infotrieve].
11.
Nakamura T, Alder H, Gu Y, et al.
Genes on chromosomes 4, 9, and 19 involved in 11q23 abnormalities in acute leukemia share sequence homology and/or common motifs.
Proc Natl Acad Sci U S A.
1993;90:4631-4635
12.
Domer PH, Fakharzadeh SS, Chen CS, et al.
Acute mixed-lineage leukemia t(4;11)(q21;q23) generates an MLL-AF4 fusion product.
Proc Natl Acad Sci. U S A.
1993;90:7884-7888
13.
Taki T, Kano H, Taniwaki M, Sako M, Yanagisawa M, Hayashi Y.
AF5q31, a newly identified AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia with ins(5;11)(q31;q13q23).
Proc Natl Acad Sci U S A.
1999;96:14535-14540
14.
Prasad R, Yano T, Sorio C, et al.
Domains with transcriptional regulatory activity within the ALL1 and AF4 proteins involved in acute leukemia.
Proc Natl Acad Sci U S A.
1995;92:12160-12164
15.
Rubnitz JE, Morrissey J, Savage PA, Cleary ML.
ENL, the gene fused with HRX in t(11;19) leukemias, encodes a nuclear protein with transcriptional activation potential in lymphoid and myeloid cells.
Blood.
1994;84:1747-1752
16.
Sobulo OM, Borrow J, Tomek R, et al.
MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3).
Proc Natl Acad Sci U S A.
1997;94:8732-8737
17.
Ida K, Kitabayashi I, Taki T, et al.
Adenoviral E1A-associated protein p300 is involved in acute myeloid leukemia with t(11;22)(q23;q13).
Blood.
1997;90:4699-4704 18. Corral J, Lavenir I, Impey H, et al. An Mll-Af9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell. 1996;85:853-861[CrossRef][Medline] [Order article via Infotrieve]. 19. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 1997;16:4226-4237[CrossRef][Medline] [Order article via Infotrieve]. 20. Lavau C, Du C, Thirman M, Zeleznik-Le N. Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J. 2000;19:4655-4664[CrossRef][Medline] [Order article via Infotrieve].
21.
Lavau C, Luo RT, Du C, Thirman MJ.
Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice.
Proc Natl Acad Sci U S A.
2000;97:10984-10989 22. Gietz RD, Triggs-Raine B, Robbins A, Graham KC, Woods RA. Identification of proteins that interact with a protein of interest: applications of the yeast two-hybrid system. Mol Cell Biochem. 1997;172:67-79[CrossRef][Medline] [Order article via Infotrieve]. 23. Altschul SF, Gish W. Local alignment statistics. Methods Enzymol. 1996;26:460-480.
24.
Thirman MJ, Diskin EB, Bin SS, Ip HS, Miller JM, Simon MC.
Developmental analysis and subcellular localization of the murine homologue of ELL.
Proc Natl Acad Sci U S A.
1997;94:1408-1413 25. Lillie JW, Green MR. Transcription activation by the adenovirus E1a protein. Nature. 1989;338:39-44[CrossRef][Medline] [Order article via Infotrieve].
26.
Ma C, Staudt LM.
LAF-4 encodes a lymphoid nuclear protein with transactivation potential that is homologous to AF-4, the gene fused to MLL in t(4;11) leukemias.
Blood.
1996;87:734-745 27. von Bergh A, Beverloo B, Slater R, et al. Cloning of unknown MLL fusion transcripts indentifies two novel MLL fusion partners [abstract]. Blood. 2000;96:2984a. 28. Gecz J, Bielby S, Sutherland GR, Mulley JC. Gene structure and subcellular localization of FMR2, a member of a new family of putative transcription activators. Genomics. 1997;44:201-213[CrossRef][Medline] [Order article via Infotrieve].
29.
Maki K, Mitani K, Yamagata T, et al.
Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia.
Blood.
1999;93:3216-3224
30.
Shinobu N, Maeda T, Aso T, et al.
Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53.
J Biol Chem.
1999;274:17003-17010
31.
Schmidt AE, Miller T, Schmidt SL, Shiekhattar R, Shilatifard A.
Cloning and characterization of the EAP30 subunit of the ELL complex that confers derepression of transcription by RNA polymerase II.
J Biol Chem.
1999;274:21981-21985
32.
Butler LH, Slany R, Cui X, Cleary ML, Mason DY.
The HRX proto-oncogene product is widely expressed in human tissues and localizes to nuclear structures.
Blood.
1997;89:3361-3370
33.
Li Q, Frestedt JL, Kersey JH.
AF4 encodes a ubiquitous protein that in both native and MLL-AF4 fusion types localizes to subnuclear compartments.
Blood.
1998;92:3841-3847 34. Misteli T, Caceres JF, Spector DL. The dynamics of a pre-mRNA splicing factor in living cells. Nature. 1997;387:523-527[CrossRef][Medline] [Order article via Infotrieve].
35.
Kim E, Du L, Bregman DB, Warren SL.
Splicing factors associate with hyperphosphorylated RNA polymerase II in the absence of pre-mRNA.
J Cell Biol.
1997;136:19-28 36. Dyck JA, Maul GG, Miller WH Jr, Chen JD, Kakizuka A, Evans RM. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell. 1994;76:333-343[CrossRef][Medline] [Order article via Infotrieve]. 37. Weis K, Rambaud S, Lavau C, et al. Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell. 1994;76:345-356[CrossRef][Medline] [Order article via Infotrieve]. 38. Luo RT, Lavau C, Thirman MJ. The EAF1 interaction domain of ELL is essential but its elongation domain is dispensable for the immortalization of hematopoietic progenitor cells by MLL-ELL [abstract]. Blood. 1999;94:220a. 39. Yankulov K, Blau J, Purton T, Roberts S, Bentley DL. Transcriptional elongation by RNA polymerase II is stimulated by transactivators. Cell. 1994;77:749-759[CrossRef][Medline] [Order article via Infotrieve]. 40. Brown SA, Weirich CS, Newton EM, et al. Transcriptional activation domains stimulate initiation and elongation at different times and via different residues. EMBO J. 1998;17:3146-3154[CrossRef][Medline] [Order article via Infotrieve].
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. Zhou, X. Feng, B. Ban, J. Liu, Z. Wang, and W. Xiao Elongation Factor ELL (Eleven-Nineteen Lysine-rich Leukemia) Acts as a Transcription Factor for Direct Thrombospondin-1 Regulation J. Biol. Chem., July 10, 2009; 284(28): 19142 - 19152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Slany The molecular biology of mixed lineage leukemia Haematologica, July 1, 2009; 94(7): 984 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-X. Liu, B. Hu, Y. Wang, J.-F. Gui, and W. Xiao Zebrafish eaf1 and eaf2/u19 Mediate Effective Convergence and Extension Movements through the Maintenance of wnt11 and wnt5 Expression J. Biol. Chem., June 12, 2009; 284(24): 16679 - 16692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. R. Smith, B. Winter, J. C. Eissenberg, and A. Shilatifard Regulation of the transcriptional activity of poised RNA polymerase II by the elongation factor ELL PNAS, June 24, 2008; 105(25): 8575 - 8579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. S. Banks, S. E. Kong, H. Spahr, L. Florens, S. Martin-Brown, M. P. Washburn, J. W. Conaway, A. Mushegian, and R. C. Conaway Identification and Characterization of a Schizosaccharomyces pombe RNA Polymerase II Elongation Factor with Similarity to the Metazoan Transcription Factor ELL J. Biol. Chem., February 23, 2007; 282(8): 5761 - 5769. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. Kong, C. A. S. Banks, A. Shilatifard, J. W. Conaway, and R. C. Conaway ELL-associated factors 1 and 2 are positive regulators of RNA polymerase II elongation factor ELL PNAS, July 19, 2005; 102(29): 10094 - 10098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. P. Yam, D.-Y. Jin, C. W. So, and L. C. Chan Identification and characterization of EBP, a novel EEN binding protein that inhibits Ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein Blood, February 15, 2004; 103(4): 1445 - 1453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Hackett, J. G. Hodgson, M. E. Law, J. Fridlyand, K. Osoegawa, P. J. de Jong, N. J. Nowak, D. Pinkel, D. G. Albertson, A. Jain, et al. Genome-wide Array CGH Analysis of Murine Neuroblastoma Reveals Distinct Genomic Aberrations which Parallel those in Human Tumors Cancer Res., September 1, 2003; 63(17): 5266 - 5273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Xiao, Q. Zhang, F. Jiang, M. Pins, J. M. Kozlowski, and Z. Wang Suppression of Prostate Tumor Growth by U19, a Novel Testosterone-regulated Apoptosis Inducer Cancer Res., August 1, 2003; 63(15): 4698 - 4704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Saso, T. Ito, S. Natori, and K. Sekimizu Identification of a Novel Tissue-Specific Transcriptional Activator FESTA as a Protein That Interacts with the Transcription Elongation Factor S-II J. Biochem., April 1, 2003; 133(4): 493 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Polak, F. Simone, J. J. Kaberlein, R. T. Luo, and M. J. Thirman ELL and EAF1 are Cajal Body Components That Are Disrupted in MLL-ELL Leukemia Mol. Biol. Cell, April 1, 2003; 14(4): 1517 - 1528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Simone, R. T. Luo, P. E. Polak, J. J. Kaberlein, and M. J. Thirman ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties Blood, March 15, 2003; 101(6): 2355 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. T. Luo, C. Lavau, C. Du, F. Simone, P. E. Polak, S. Kawamata, and M. J. Thirman The Elongation Domain of ELL Is Dispensable but Its ELL-Associated Factor 1 Interaction Domain Is Essential for MLL-ELL-Induced Leukemogenesis Mol. Cell. Biol., August 15, 2001; 21(16): 5678 - 5687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. W. Baron, J. Anastasi, M. J. Thirman, Y. Furukawa, S. Fears, D. C. Kim, F. Simone, M. Birkenbach, A. Montag, A. Sadhu, et al. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: Implications for a role of BCL6 in the down-regulation of apoptosis PNAS, March 5, 2002; 99(5): 2860 - 2865. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
